Patients With Chronic HCV May Have Clinical Benefits With DAA That May Persist, Become More Apparent In Long-Term Follow-Up, Study Suggests

February 20, 2020

Infectious Disease Advisor (2/19, Schad) reports “combination therapy with direct-acting antiviral agents (DAAs) confers real clinical benefits in patients with chronic hepatitis C virus (HCV) infection, and these benefits appear to persist and become mor...